Tadnersen
| Code | Size | Price |
|---|
| TAR-T39650-5mg | 5mg | £503.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
Tadnersen (BIIB078), an antisense oligonucleotide (ASO), selectively targets C9ORF72 transcript variants 1 and 3 that carry the expansion.
CAS:
2170507-65-8
Formula:
0
Molecular Weight:
0
Purity:
0.98
SMILES:
0
References
Aoki Y, et al. Emerging Oligonucleotide Therapeutics for Rare Neuromuscular Diseases [published online ahead of print, 2021 Jun 3]. J Neuromuscul Dis. 2021;10.3233/JND-200560.
Smeyers J, et al. C9ORF72: What It Is, What It Does, and Why It Matters. Front Cell Neurosci. 2021;15:661447. Published 2021 May 5.